nach oben

Erschienen in:

10.02.2019 | Original Article

Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine

verfasst von: Ainur Nurpeisova, Markhabat Kassenov, Nurkuisa Rametov, Kaissar Tabynov, Gourapura J. Renukaradhya, Yevgeniy Volgin, Altynay Sagymbay, Amanzhol Makbuz, Abylay Sansyzbay, Berik Khairullin

Erschienen in: Archives of Virology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

This paper describes a preclinical study analyzing the immunogenicity and protective efficacy of Kazfluvac^®, an adjuvant-based inactivated pandemic influenza A/H5N1 virus vaccine. In this study, laboratory animals (ferrets and mice) were vaccinated by the intramuscular or intraperitoneal route at an interval of 14 days with two doses of the vaccine containing different concentrations of influenza virus hemagglutinin (HA) protein. HA protein without adjuvant (aluminum hydroxide and Merthiolate) was used as a control. As a negative control, we utilized PBS. We assessed the protective efficacy of the candidate vaccine by analyzing the response to challenge with the influenza virus strain A/chicken/Astana/6/05 (H5N1). Our experimental results revealed substantially reduced clinical disease and an increased antibody response, as determined by hemagglutination-inhibition (HAI) test and microneutralization assay (MNA). This study showed that the candidate vaccine is safe and elicits an antigen-dose-dependent serum antibody response. In summary, we determined the optimum antigen dose in a Kazfluvac^® adjuvant formulation required for induction of heightened immunogenicity and protective efficacy to mitigate H5N1 disease in experimental animals, suggesting its readiness for clinical studies in humans.

Capua I, Alexander DJ (2009) Avian influenza infection in birds: a challenge and opportunity for the poultry veterinarian. Poult Sci 88(4):842–846. https://doi.org/10.3382/ps.2008-00289 CrossRefPubMed

Beigel JH, Farrar J, Han AM et al (2005) Avian influenza A (H5N1) infection in humans. N Engl J Med 353(13):1374–1385. https://doi.org/10.1056/NEJMra052211 CrossRefPubMed

Fleming DM, Elliot AJ (2005) The impact of influenza on the health and health care utilisation of elderly people. Vaccine 23:1–9. https://doi.org/10.1016/j.vaccine.2005.04.018 CrossRef

World Health Organization (2016) Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/. Accessed 20 June 2018

Kydyrbaev ZhK, Tabynov KK, Khairullin BM (2015) Vysokopatogennyj gripp ptic: rasprostranenie v Kazahstane i razrabotka sredstv specificheskoj profilaktiki [Highly pathogenic avian influenza: distribution in Kazakhstan and development of means of specific prevention]. Almaty (in Russian)

Sansyzbay AR, Erofeeva MK, Khairullin BM et al (2013) Inactivated and adjuvanted whole virion clade 2.2 H5N1 (A/chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans. Clin Vaccine Immunol 20(8):1314–1319. https://doi.org/10.1128/CVI.00096-13 CrossRefPubMedPubMedCentral

Stukova M, Mamadaliyev S, Sandybayev N et al (2011) Basic results of development of a production technology and control of a pandemic influenza A/H5N1 vaccine. Influenza Other Respir Viruses 5(1):350–353

Nurpeysova A, Khairullin B, Kassenov M et al (2011) Preclinical testing of Kazfluvac^®, a vaccine against pandemic influenza A/H5N1v. J Pharm Biomed Sci 1(5):108–112

Langley JM, Frenette L, Ferguson L et al (2010) Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 201(11):1644–1653. https://doi.org/10.1086/652701 CrossRefPubMed

10.

Li H, Nookala S, Re F (2007) Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1β and IL-18 release. J Immunol 178(8):5271–5276. https://doi.org/10.4049/jimmunol.178.8.5271 CrossRefPubMed

11.

Cox JC, Coulter AR (1997) Adjuvants—a classification and review of their modes of action. Vaccine 15(3):248–256. https://doi.org/10.1016/S0264-410X(96)00183-1 CrossRefPubMed

12.

Lambert LC, Fauci AS (2010) Influenza vaccines for the future. N Engl J Med 363(21):2036–2044. https://doi.org/10.1056/NEJMra1002842 CrossRefPubMed

13.

Bodewes R, Osterhaus AD, Rimmelzwaan GF (2010) Targets for the induction of protective immunity against influenza a viruses. Viruses 2(1):166–188. https://doi.org/10.3390/v2010166 CrossRefPubMedPubMedCentral

14.

Treanor JJ, Campbell JD, Zangwill KM et al (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354(13):1343–1351. https://doi.org/10.1056/NEJMoa055778 CrossRefPubMed

15.

Nichol KL, Treanor JJ (2006) Vaccines for seasonal and pandemic influenza. J Infect Dis 194(2):111–118. https://doi.org/10.1086/507544 CrossRef

16.

Monto AS (2006) Vaccines and antiviral drugs in pandemic preparedness. Emerg Infect Dis 12(1):55. https://doi.org/10.3201/eid1201.051068 CrossRefPubMedPubMedCentral

17.

Langlois I (2005) Viral diseases of ferrets. Vet Clin N Am Exot Anim Pract 8(1):139–160. https://doi.org/10.1016/j.cvex.2004.09.008 CrossRef

18.

Belser JA, Katz JM, Tumpey TM (2011) The ferret as a model organism to study influenza A virus infection. Dis Model Mech 4(5):575–579. https://doi.org/10.1242/dmm.007823 CrossRefPubMedPubMedCentral

19.

Palmer D, Dowdle W, Coleman M et al (1975) Advanced laboratory techniques for influenza diagnosis. Immunology series no. 6. Part 2, procedural guide. US Department of Health Education and Public Health Service, Atlanta, pp 25–62

20.

Huprikar J, Rabinowitz S (1980) A simplified plaque assay for influenza viruses in Madin–Darby kidney (MDCK) cells. J Virol Methods 1(2):117–120. https://doi.org/10.1016/0166-0934(80)90020-8 CrossRefPubMed

21.

Asanzhanova NN, Ryskeldinova SZ, Chervyakova OV et al (2017) Comparison of different methods of purification and concentration in production of influenza vaccine. Bull Exp Biol Med 164(2):229–232. https://doi.org/10.1007/s10517-017-3964-y CrossRefPubMed

22.

Ferko B, Stasakova J, Romanova J et al (2004) Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol 78(23):13037–13045. https://doi.org/10.1128/JVI.78.23.13037-13045.2004 CrossRefPubMedPubMedCentral

23.

Lin J, Zhang J, Dong X et al (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368(9540):991–997. https://doi.org/10.1016/S0140-6736(06)69294-5 CrossRefPubMed

24.

Luke CJ, Subbaro K (2006) Vaccines for pandemic influenza. Emerg Infect Dis 12(1):66–72. https://doi.org/10.3201/eid1201.051147 CrossRefPubMedPubMedCentral

25.

Palese P (2006) Making better influenza virus vaccines? Emerg Infect Dis 12(1):61–65. https://doi.org/10.3201/eid1201.051043 CrossRefPubMedPubMedCentral

26.

Horimoto T, Takada A, Fujii K et al (2006) The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 24(17):3669–3676. https://doi.org/10.1016/j.vaccine.2005.07.005 CrossRefPubMed

27.

De Jonge J, Isakova-Sivak I, Van Dijken H et al (2016) H7N9 live attenuated influenza vaccine is highly immunogenic, prevents virus replication, and protects against severe bronchopneumonia in ferrets. Mol Ther 24(5):991–1002. https://doi.org/10.1038/mt.2016.23 CrossRefPubMedPubMedCentral

28.

Baz M, Boonnak K, Paskel M et al (2015) Nonreplicating influenza A virus vaccines confer broad protection against lethal challenge. MBio 6(5):01487-15. https://doi.org/10.1128/mBio.01487-15 CrossRef

29.

Music N, Reber AJ, Kim MC et al (2016) Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets. Vaccine 34(4):466–473. https://doi.org/10.1016/j.vaccine.2015.12.023 CrossRefPubMed

30.

Baker SF, Guo H, Albrecht RA et al (2013) Protection against lethal influenza with a viral mimic. J Virol 87(15):8591–8605. https://doi.org/10.1128/JVI.01081-13 CrossRefPubMedPubMedCentral

31.

Maher JA, DeStefano J (2004) The ferret: an animal model to study influenza virus. Lab Anim (NY) 33(9):50–53. https://doi.org/10.1038/laban1004-50 CrossRef

32.

Bosch BJ, Bodewes R, de Vries RP et al (2010) Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A (H1N1) influenza virus infection in ferrets. J Virol 84(19):10366–10374. https://doi.org/10.1128/JVI.01035-10 CrossRefPubMedPubMedCentral

33.

Lipatov AS, Webby RJ, Govorkova EA et al (2005) Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 191(8):1216–1220. https://doi.org/10.1086/428951 CrossRefPubMed

34.

Johansen K, Nicoll A, Ciancio BC et al (2009) Pandemic influenza A (H1N1) 2009 vaccines in the European Union. Euro Surveill 14(41):19361PubMed

35.

Kassenov MM, Khairullin BM, Kydyrbayev ZhK et al (2010) Influenza monitoring among birds in Kostanaiskaya Oblast, Republic of Kazakhstan. Agric Biol J N Am 1(5):737–739. https://doi.org/10.5251/abjna.2010.1.5.737.739 CrossRef

36.

Katz J, Hancock K, Veguilla V et al (2009) Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 58(19):521–524

37.

Liu G, Song L, Reiserova L et al (2012) Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections. Vaccine 30(48):6833–6838. https://doi.org/10.1016/j.vaccine.2012.09.013 CrossRefPubMed

38.

Ninomiya A, Imai M, Tashiro M et al (2007) Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25(18):3554–3560. https://doi.org/10.1016/j.vaccine.2007.01.083 CrossRefPubMed

39.

Schultze V, D’Agosto V, Wack A et al (2008) Safety of MF59™ adjuvant. Vaccine 26(26):3209–3222. https://doi.org/10.1016/j.vaccine.2008.03.093 CrossRefPubMed

40.

Tabynov K, Kydyrbayev Zh, Sansyzbay A et al (2012) Immunogenic and protective properties of the first kazakhstan vaccine against pandemic influenza A (H1N1) pdm09 in ferrets. Virol Sin 27(6):344–351. https://doi.org/10.1007/s12250-012-3272-7 CrossRef

Titel: Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine
verfasst von: Ainur Nurpeisova
Markhabat Kassenov
Nurkuisa Rametov
Kaissar Tabynov
Gourapura J. Renukaradhya
Yevgeniy Volgin
Altynay Sagymbay
Amanzhol Makbuz
Abylay Sansyzbay
Berik Khairullin
Publikationsdatum: 10.02.2019
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 4/2019
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-019-04147-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Prokaryotic expression, purification and evaluation of goatpox virus ORF117 protein as a diagnostic antigen in indirect ELISA to detect goatpox

Porcine epidemic diarrhea virus nsp4 induces pro-inflammatory cytokine and chemokine expression inhibiting viral replication in vitro

Construction and characterization of porcine single-chain fragment variable antibodies that neutralize transmissible gastroenteritis virus in vitro

Expression profiling and regulatory network of cucumber microRNAs and their putative target genes in response to cucumber green mottle mosaic virus infection

Detection of adenovirus, papillomavirus and parvovirus in Brazilian bats of the species Artibeus lituratus and Sturnira lilium

Interaction of the intrinsically disordered C-terminal domain of the sesbania mosaic virus RNA-dependent RNA polymerase with the viral protein P10 in vitro: modulation of the oligomeric state and polymerase activity

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin